排序方式: 共有247条查询结果,搜索用时 546 毫秒
1.
2.
3.
Analysis and comparison of statin prescription patterns and outcomes according to clinical department 下载免费PDF全文
4.
5.
Effect of smoking status on progression‐free and overall survival in non‐small cell lung cancer patients receiving erlotinib or gefitinib: a meta‐analysis 下载免费PDF全文
6.
Kara J. Walters PharmD Anna Meador PharmD BCACP John A. Galdo PharmD BCPS CGP Katharine Ciarrocca DMD MSEd 《Special care in dentistry》2017,37(2):62-70
Coagulation disorders account for a high incidence of death in the U.S. due to stroke, myocardial infarction, and venous thromboembolism. In the past few years, numerous agents have been brought to market for the treatment of thromboembolism or prevention of thromboembolism. Similar to warfarin, these agents can cause bleeding disorders, which may exacerbate dental care treatment plans. This literature review examines the newer agents for the treatment of thromboembolism disorders, common side effects and drug interactions, the specific medical conditions each agent treats, and the dental perspective on how to medically management patients prescribed these medications. 相似文献
7.
Shahar Shmuel PhD Virginia Pate MS Marc J. Pepin PharmD BCPS BCGP Janine C. Bailey PharmD BCPS Yvonne M. Golightly PT MS PhD Laura C. Hanson MD MPH Til Stürmer MD MPH PhD Rebecca B. Naumann PhD Danijela Gnjidic PhD Jennifer L. Lund PhD 《Journal of the American Geriatrics Society》2021,69(11):3212-3224
8.
Implementation and Preliminary Clinical Outcomes of a Pharmacist‐managed Venous Thromboembolism Clinic for Patients Treated With Rivaroxaban Post Emergency Department Discharge 下载免费PDF全文
Baely M. DiRenzo PharmD BCPS Daren M. Beam MD MS Jeffrey A. Kline MD Karishma S. Deodhar PharmD BCPS Zachary A. Weber PharmD BCPS BCACP CDE Christie M. Davis PharmD BCPS Todd A. Walroth PharmD BCPS BCCCP 《Academic emergency medicine》2018,25(6):634-640
Objective
The objective was to describe the implementation, work flow, and differences in outcomes between a pharmacist‐managed clinic for the outpatient treatment of venous thromboembolism (VTE) using a non‐vitamin K oral anticoagulant versus care by a primary care provider (PCP).Methods
Patients in the studied health system that are diagnosed with low‐risk VTE in the emergency department are often discharged without hospital admission. These patients are treated with a non‐vitamin K oral anticoagulant and follow‐up either in a pharmacist‐managed VTE clinic or with their PCP. Pharmacists in the VTE clinic work independently under a collaborative practice agreement (CPA). An evaluation of 34 patients, 17 in each treatment arm, was conducted to compare the differences in treatment‐related outcomes of rivaroxaban when managed by a pharmacist versus a PCP.Results
The primary endpoint was a 6‐month composite of anticoagulation treatment‐related complications that included a diagnosis of major bleeding, recurrent thromboembolism, or fatality due to either major bleeding or recurrent thromboembolism. Secondary endpoints included number of hospitalizations, adverse events, and medication adherence. There was no difference in the primary endpoint between groups with one occurrence of the composite endpoint in each treatment arm (p = 1.000), both of which were recurrent thromboembolic events. Medication adherence assessment was formally performed in eight patients in the pharmacist group versus no patients in the control group. No differences were seen among other secondary endpoints.Conclusions
The pharmacist‐managed clinic is a novel expansion of clinical pharmacy services that treats patients with low‐risk VTEs with rivaroxaban in the outpatient setting. The evaluation of outcomes provides support that pharmacist‐managed care utilizing standardized protocols under a CPA may be as safe as care by a PCP.9.
Slow Infusion of Low‐dose Ketamine Reduces Bothersome Side Effects Compared to Intravenous Push: A Double‐blind,Double‐dummy,Randomized Controlled Trial 下载免费PDF全文
Eben J. Clattenburg MD MPH Christian Hailozian Daniel Haro Tina Yoo PharmD Stefan Flores MD Derex Louie PharmD BCPS Andrew A. Herring MD 《Academic emergency medicine》2018,25(9):1048-1052
Objective
We compared the analgesic efficacy and incidence of side effects when low‐dose (0.3 mg/kg) ketamine (LDK) is administered as a slow infusion (SI) over 15 minutes versus an intravenous push (IVP) over 1 minute.Methods
This was a prospective, randomized, double‐blind, double‐dummy, placebo‐controlled trial of adult ED patients presenting with moderate to severe pain (numerical rating scale [NRS] score ≥ 5). Patients received 0.3 mg/kg ketamine administered either as a SI or a IVP. Our primary outcome was the proportion of patients experiencing any psychoperceptual side effect over 60 minutes. A secondary outcome was incidence of moderate or greater psychoperceptual side effects. Additional outcomes included reduction in pain NRS scores at 60 minutes and percent maximum summed pain intensity difference (%SPID).Results
Fifty‐nine participants completed the study. A total of 86.2% of the IVP arm and 70.0% of the SI arm experienced any side effect (difference = 16.2%, 95% confidence interval [CI] = –5.4 to 37.8). We found a large reduction in moderate or greater psychoperceptual side effects with SI administration—75.9% reported moderate or greater side effects versus 43.4% in the SI arm (difference = 32.5%, 95% CI = 7.9 to 57.1). Additionally, the IVP arm experienced more hallucinations (n = 8, 27.6%) than the SI arm (SI n = 2, 6.7%, difference = 20.9%, 95% CI = 1.8 to 43.4). We found no significant differences in analgesic efficacy. At 60 minutes, the mean %SPID values in the IVP and SI arms were 39.9 and 33.5%, respectively, with a difference of 6.5% (95% CI = –5.8 to 18.7).Conclusion
Most patients who are administered LDK experience a psychoperceptual side effect regardless of administration via SI or IVP. However, patients receiving LDK as a SI reported significantly fewer moderate or greater psychoperceptual side effects and hallucinations with equivalent analgesia.10.